A net-work meta-analysis of the cardiac safety for next-generation hormonal agents in treating castration-resistant prostate cancer: How to choose drugs appropriately?

被引：1
作者：
Liang, Zhen [1 ]
Wang, Juan [1 ]
Feng, Tianrui [1 ]
Chen, Yuliang [1 ]
Zhou, Zhien [1 ]
Zhou, Yi [1 ]
Yan, Weigang [1 ,3 ]
Cao, Fenghong [2 ]
机构：
[1] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Peking Union Med Coll, Dept Urol, Beijing, Peoples R China
[2] North China Univ Sci & Technol, Affiliated Hosp, Dept Urol, 73 Jianshe South Rd, Tangshan 063000, Hebei, Peoples R China
[3] Peking Union Med Coll Hosp, Dept Urol, Surg Bldg,1 Shuaifuyuan, Beijing 100730, Peoples R China
来源：
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2024年 / 196卷
关键词：
Androgen deprivation therapy; Cardiovascular disease; Prostate cancer; ANDROGEN-DEPRIVATION THERAPY; ABIRATERONE ACETATE; DOUBLE-BLIND; CARDIOVASCULAR-DISEASE; SYSTEMATIC REVIEWS; INCREASED SURVIVAL; MEN; ENZALUTAMIDE; ASSOCIATION; BICALUTAMIDE;
D O I：
10.1016/j.critrevonc.2024.104273
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Background: Researchers have shown that using next-generation hormonal agents (NHA) for castration-resistant prostate cancer (CRPC) would lead to increased risk of cardiac adverse effects, making clinician choices more complex. Methods: We systematically searched Pubmed, Cochrane Library, and Embase databases for research published before October 2022. Agents were ranked according to their effectiveness based on cardiac adverse effects using the surface under the cumulative ranking curve. Results: A total of 21 Randomized Controlled Trials (RCT) with 19, 083 patients were included in present study. Our results showed that abiraterone and enzalutamide could lead to a significantly higher hypertension rate compared with placebo; whereas no significant difference was detected between four NHAs and placebo in ischemic heart disease incidence. All four NHAs could significantly increase the risk of cardiotoxicity. Conclusions: NHAs are generally acceptable in terms of cardiovascular disease compared to placebo in patients with CRPC.
引用
收藏
页数：12
相关论文
共 60 条
  • [1] Ra-223 induces clustered DNA damage and inhibits cell survival in several prostate cancer cell lines
    Abramenkovs, Andris
    Hariri, Mehran
    Spiegelberg, Diana
    Nilsson, Sten
    Stenerlow, Bo
    [J]. TRANSLATIONAL ONCOLOGY, 2022, 26
  • [2] Deep androgen receptor suppression in prostate cancer exploits sexually dimorphic renal expression for systemic glucocorticoid exposure
    Alyamani, M.
    Li, J.
    Patel, M.
    Taylor, S.
    Nakamura, F.
    Berk, M.
    Przybycin, C.
    Posadas, E. M.
    Madan, R. A.
    Gulley, J. L.
    Rini, B.
    Garcia, J. A.
    Klein, E. A.
    Sharifi, N.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 (03) : 369 - 376
  • [3] Population, Intervention, Comparison, Outcomes and Study (PICOS) design as a framework to formulate eligibility criteria in systematic reviews
    Amir-Behghadami, Mehrdad
    Janati, Ali
    [J]. EMERGENCY MEDICINE JOURNAL, 2020, 37 (06) : 387 - 387
  • [4] ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer
    Armstrong, Andrew J.
    Szmulewitz, Russell Z.
    Petrylak, Daniel P.
    Holzbeierlein, Jeffrey
    Villers, Arnauld
    Azad, Arun
    Alcaraz, Antonio
    Alekseev, Boris
    Iguchi, Taro
    Shore, Neal D.
    Rosbrook, Brad
    Sugg, Jennifer
    Baron, Benoit
    Chen, Lucy
    Stenzl, Arnulf
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (32) : 2974 - +
  • [5] Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven
    Attard, Gerhardt
    Reid, Alison H. M.
    Yap, Timothy A.
    Raynaud, Florence
    Dowsett, Mitch
    Settatree, Sarah
    Barrett, Mary
    Parker, Christopher
    Martins, Vanessa
    Folkerd, Elizabeth
    Clark, Jeremy
    Cooper, Colin S.
    Kaye, Stan B.
    Dearnaley, David
    Lee, Gloria
    de Bono, Johann S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (28) : 4563 - 4571
  • [6] Assessment of the Safety of Glucocorticoid Regimens in Combination With Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer: A Randomized, Open-label Phase 2 Study
    Attard, Gerhardt
    Merseburger, Axel S.
    Arlt, Wiebke
    Sternberg, Cora N.
    Feyerabend, Susan
    Berruti, Alfredo
    Joniau, Steven
    Geczi, Lajos
    Lefresne, Florence
    Lahaye, Marjolein
    Shelby, Florence Nave
    Pissart, Genevieve
    Chua, Sue
    Jones, Robert J.
    Tombal, Bertrand
    [J]. JAMA ONCOLOGY, 2019, 5 (08) : 1159 - 1167
  • [7] Darolutamide For Castration-Resistant Prostate Cancer
    Bastos, Diogo A.
    Antonarakis, Emmanuel S.
    [J]. ONCOTARGETS AND THERAPY, 2019, 12 : 8769 - 8777
  • [8] Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
    Froehner, Michael
    Wirth, Manfred P.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (18) : 1755 - 1755
  • [9] nmCRPC, a look in the continuous care of prostate cancer patients: state of art and future perspectives
    Berruti, Alfredo
    Bracarda, Sergio
    Caffo, Orazio
    Cortesi, Enrico
    D'Angelillo, Rolando
    Del Re, Marzia
    Facchini, Gaetano
    Pappagallo, Giovanni
    Procopio, Giuseppe
    Sabbatini, Roberto
    Santini, Daniele
    [J]. CANCER TREATMENT REVIEWS, 2023, 115
  • [10] Cardiovascular Effects of Androgen Deprivation Therapy for the Treatment of Prostate Cancer ABCDE Steps to Reduce Cardiovascular Disease in Patients With Prostate Cancer
    Bhatia, Nirmanmoh
    Santos, Marilia
    Jones, Lee W.
    Beckman, Joshua A.
    Penson, David F.
    Morgans, Alicia K.
    Moslehi, Javid
    [J]. CIRCULATION, 2016, 133 (05) : 537 - 541
123456